Search Instructions:
* Filter the ENTIRE resource library: Choose a Subject OR a Type of Item at the bottom of the page from the buttons to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (62 total)
Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination
Creator: Bayas, Antonios, Martina Menacher, Monika Christ, Lars Behrens, Andreas Rank, and Markus Naumann.
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-04-14
Description: Clinical Picture of Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination in a 55-year-old woman
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-04-14
Description: Clinical Picture of Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination in a 55-year-old woman
Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination
Creator: Muster, Viktoria, Thomas Gary, Reinhard B. Raggam, Albert WÖlfler, and Marianne Brodmann.
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-04-14
Description: Clinical Picture of a Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination in a 51-year-old woman
Subject: Treatment & Care
Item Type: Publication
Date Last Updated: 2021-04-14
Description: Clinical Picture of a Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination in a 51-year-old woman
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Creator: Greinacher, Andreas, Thomas Thiele, Theodore E. Warkentin, Karin Weisser, Paul A. Kyrle, and Sabine Eichinger.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1…
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Creator: Schultz, Nina H., Ingvild H. Sørvoll, Annika E. Michelsen, Ludvig A. Munthe, Fridtjof Lund-Johansen, Maria T. Ahlen, Markus Wiedmann, Anne-Hege Aamodt, Thor H. Skattør, Geir E. Tjønnfjord, and Pål A. Holme.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19).
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-09
Description: We report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1 nCoV-19 adenoviral vector vaccine against coronavirus disease 2019 (Covid-19).
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Creator: the mRNA-1273 Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-06
Description: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-06
Description: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
Creator: Joyner, Michael J., Rickey E. Carter, Jonathon W. Senefeld, Stephen A. Klassen, John R. Mills, Patrick W. Johnson, Elitza S. Theel, Chad C. Wiggins, Katelyn A. Bruno, Allan M. Klompas, Elizabeth R. Lesser, Katie L. Kunze, Matthew A. Sexton, Juan C.…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-18
Description: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-18
Description: Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be…
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California
Creator: Keehner, Jocelyn, Lucy E. Horton, Michael A. Pfeffer, Christopher A. Longhurst, Robert T. Schooley, Judith S. Currier, Shira R. Abeles, and Francesca J. Torriani.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-23
Description: Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-03-23
Description: Data from phase 3 clinical trials of messenger RNA (mRNA) vaccines through November 2020 showed 94.1% efficacy for the prevention of symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection at 14 days after the second dose…